Physician profile
Elizabeth H Eversmann
NPI 1528051182
$3,988.00
in general payments reported to CMS, 2019-2025
30 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,256 · 2022: $758 · 2023: $1,078 · 2024: $433 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.72 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.08 | 2021-2025 | |
| Lilly USA, LLC | $773.88 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $702.00 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $192.77 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.89 | 2022 | |
| Amgen INC. | $147.33 | 2021 | |
| Glaxosmithkline, LLC. | $128.38 | 2021-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.47 | 2021-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.43 | 2021-2022 | |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Pfizer INC. | $72.45 | 2023-2024 | |
| Esperion Therapeutics, INC. | $68.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $67.32 | 2021-2023 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $39.46 | 2021 | |
| Sumitomo Pharma America, INC. | $38.31 | 2023 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.83 | 2021-2024 | |
| Harmony Biosciences LLC | $31.44 | 2025 | |
| Eisai INC. | $28.65 | 2021-2022 | |
| Axsome Therapeutics, INC. | $27.53 | 2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $27.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.78 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $18.70 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.62 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.98 | 2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $14.51 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.78 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $12.90 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $11.69 | 2021 | |
| Radius Health, INC. | $11.21 | 2021 | |
| Genentech USA, INC. | $10.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Eversmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.